{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wan J"],"funding":["Natural Science Foundation of Hubei Province of China","National Natural Science Foundation of China"],"pagination":["284"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10440922"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(1)"],"pubmed_abstract":["Osteoarthritis (OA) is a common degenerative joint disease urgently needing effective treatments. Bone marrow mesenchymal stromal cell-derived exosomes (Exo) are considered good drug carriers whereas they have limitations such as fast clearance and low retention. This study aimed to overcome the limitations of Exo in drug delivery using multiple strategies. Novel photocrosslinking spherical gelatin methacryloyl hydrogel (GelMA)-encapsulated cartilage affinity WYRGRL (W) peptide-modified engineered Exo were developed for OA treatment and the performance of the engineered Exo (W-Exo@GelMA) loaded with a small inhibitor LRRK2-IN-1 (W-Exo-L@GelMA) was investigated in vitro and in vivo. The W-Exo-L@GelMA showed an effective targeting effect on chondrocytes and a pronounced action on suppressing"],"journal":["Journal of nanobiotechnology"],"pubmed_title":["Injectable photocrosslinking spherical hydrogel-encapsulated targeting peptide-modified engineered exosomes for osteoarthritis therapy."],"pmcid":["PMC10440922"],"funding_grant_id":["2020CFB216","81672168"],"pubmed_authors":["Chen A","Zhu Z","He Z","Zhang J","Cheng P","Peng R","Cui J","Wan J","Hao X","Wu X"],"additional_accession":[]},"is_claimable":false,"name":"Injectable photocrosslinking spherical hydrogel-encapsulated targeting peptide-modified engineered exosomes for osteoarthritis therapy.","description":"Osteoarthritis (OA) is a common degenerative joint disease urgently needing effective treatments. Bone marrow mesenchymal stromal cell-derived exosomes (Exo) are considered good drug carriers whereas they have limitations such as fast clearance and low retention. This study aimed to overcome the limitations of Exo in drug delivery using multiple strategies. Novel photocrosslinking spherical gelatin methacryloyl hydrogel (GelMA)-encapsulated cartilage affinity WYRGRL (W) peptide-modified engineered Exo were developed for OA treatment and the performance of the engineered Exo (W-Exo@GelMA) loaded with a small inhibitor LRRK2-IN-1 (W-Exo-L@GelMA) was investigated in vitro and in vivo. The W-Exo-L@GelMA showed an effective targeting effect on chondrocytes and a pronounced action on suppressing","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Aug","modification":"2025-04-26T14:35:54.354Z","creation":"2025-04-06T14:35:50.312Z"},"accession":"S-EPMC10440922","cross_references":{"pubmed":["37605203"],"doi":["10.1186/s12951-023-02050-7"]}}